Evidence map›Paper›PMID 21986282›Full record

ArticleCirculation2011

Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease.

Carlos O Mendivil, Eric B Rimm, Jeremy Furtado, Stephanie E Chiuve, Frank M Sacks

Open access · bronzeAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 2 pooled it
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 2 syntheses or guidelines pooled it, 134 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Apo CIII Proteoforms, Plasma Lipids, and Cardiovascular Risk in MESA.Arteriosclerosis, thrombosis, and vascular biology · 2023
    Observational
  19. Article
  20. Review

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Carlos O MendivilHarvard School of Public Health, Department of Nutrition, 665 Huntington Avenue, Boston, MA 02115, USA.
Eric B Rimm
Jeremy Furtado
Stephanie E Chiuve
Frank M Sacks
Harvard University · US

Funding

HARVARD CLINICAL AND TRANSLATIONAL SCIENCE CENTER (UL1)UL1RR025758 · NCRR · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2008 to 2011
$91.4M
VLDL and LDL Particle Types as CHD Risk FactorsR01HL070159 · NHLBI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI SACKS, FRANK M · 2003 to 2006
$2.8M
NCRR NIH HHS UL1 RR025758NHLBI NIH HHS HL070159NHLBI NIH HHS R01 HL070159
6 · The paper itself

Abstract

backgroundLow-density lipoprotein (LDL) that contains apolipoprotein (apo) C-III makes up only 10% to 20% of plasma LDL but has a markedly altered metabolism and proatherogenic effects on vascular cells. METHODS AND

resultsWe examined the association between plasma LDL with apoC-III and coronary heart disease in 320 women and 419 men initially free of cardiovascular disease who developed a fatal or nonfatal myocardial infarction during 10 to 14 years of follow-up and matched controls who remained free of coronary heart disease. Concentrations of LDL with apoC-III (measured as apoB in this fraction) were associated with risk of coronary heart disease in multivariable analysis that included the ratio of total cholesterol to high-density lipoprotein cholesterol, LDL cholesterol, apoB, triglycerides, or high-density lipoprotein cholesterol and other risk factors. In all models, the relative risks for the top versus bottom quintile of LDL with apoC-III were greater than those for LDL without apoC-III. When included in the same multivariable-adjusted model, the risk associated with LDL with apoC-III (relative risk for top versus bottom quintile, 2.38; 95% confidence interval, 1.54-3.68; P for trend <0.001) was significantly greater than that associated with LDL without apoC-III (relative risk for top versus bottom quintile, 1.25; 95% confidence interval, 0.76-2.05; P for trend=0.97; P for interaction <0.001). This divergence in association with coronary heart disease persisted even after adjustment for plasma triglycerides.

conclusionsThe risk of coronary heart disease contributed by LDL appeared to result to a large extent from LDL that contains apoC-III.

Indexed as

AdultAgedApolipoprotein C-IIIApolipoproteins BCoronary DiseaseEstrogen Replacement TherapyFemaleFollow-Up StudiesHumansHypertriglyceridemiaLipoproteins, LDLLipoproteins, VLDLMaleMiddle AgedProspective StudiesRisk FactorsApolipoprotein C-IIIApolipoproteins BLipoproteins, LDLLipoproteins, VLDLTriglycerides

Identifiers

PMID21986282
PMCPMC3244212
OpenAlexW2134450273

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.